Vanguard Global Advisers
ADCT icon

Vanguard Global Advisers’s ADC Therapeutics ADCT Stock Holding History

Vanguard Global Advisers’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,593
Closed -$118K – 3641
2026
Q1 		$118K Buy
+31,593
New +$125K ﹤0.01% 2659

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Global Advisers's ADCT Position: Q2 2026 in Review

Vanguard Global Advisers sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 31,593 shares — an estimated $118K sold.

Vanguard Global Advisers first reported a position in ADCT in Q1 2026 and held it in 1 quarter. The position peaked at $118K in Q1 2026. 104 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Vanguard Global Advisers reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 31,593 ADC Therapeutics shares in Q2 2026, an estimated $118K.
  • Vanguard Global Advisers first reported a position in ADC Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's ADC Therapeutics position peaked at $118K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.